(Q37803237)

23 August 2017

title

Enfuvirtide: from basic investigations to current clinical use. (English)

1 reference

23 August 2017

Véronique Joly

1

1 reference

23 August 2017

Kaoutar Jidar

series ordinal

2

1 reference

23 August 2017

Mercedes Tatay

series ordinal

3

1 reference

23 August 2017

Patrick Yeni

series ordinal

4

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 November 2010

1 reference

Expert Opinion on Pharmacotherapy

23 August 2017

published in

1 reference

23 August 2017

volume

11

1 reference

23 August 2017

issue

16

1 reference

23 August 2017

page(s)

2701-2713

1 reference

New anti-HIV agents and targets

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Novel therapies based on mechanisms of HIV-1 cell entry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

A general model for the transmembrane proteins of HIV and other retroviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Retroviral envelope glycoproteins contain a "leucine zipper"-like repeat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

HIV-1 cell entry and advances in viral entry inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

A trimeric structural domain of the HIV-1 transmembrane glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

A spring-loaded mechanism for the conformational change of influenza hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Entry Inhibitors SCH-C, RANTES, and T-20 Block HIV Type 1 Replication in Multiple Cell Types

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Primary resistance mutations to fusion inhibitors and polymorphisms in gp41 sequences of HIV-1 non-B subtypes and recombinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Susceptibility of HIV-1 non-B subtypes and recombinant variants to Enfuvirtide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Sensitivity of HIV type 1 subtype C isolates to the entry inhibitor T-20.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Resistance to enfuvirtide, the first HIV fusion inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Enfuvirtide: a safe and effective antiretroviral agent for human immunodeficiency virus-infected patients shortly after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Cutaneous injection site reactions to long-term therapy with enfuvirtide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Does enfuvirtide increase the risk of bacterial pneumonia in patients receiving combination antiretroviral therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.522178

10.1517/14656566.2010.522178

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference